Elizabeth M Jaffee

List of Publications by Year in Descending Order

276 papers	28,082 citations	78 h-index	165 g-index
299 ext. papers	33,041 ext. citations	9.8 avg, IF	7.11 L-index

#	Paper	IF	Citations
276	Pancreatic Ductal Adenocarcinoma Cortical Mechanics and Clinical Implications.. *Frontiers in Oncology*, **2022**, 12, 809179	5.3	1
275	Neoadjuvant and adjuvant antitumor vaccination alone or combination with PD1 blockade and CD137 agonism in patients with resectable pancreatic adenocarcinoma.. *Journal of Clinical Oncology*, **2022**, 40, 558-558	2.2	2
274	Shared genetic and epigenetic changes link aging and cancer.. *Trends in Cell Biology*, **2022**,	18.3	3
273	Entinostat decreases immune suppression to promote anti-tumor responses in a HER2+ breast tumor microenvironment.. *Cancer Immunology Research*, **2022**,	12.5	1
272	Messenger RNA vaccines for cancer immunotherapy: progress promotes promise.. *Journal of Clinical Investigation*, **2022**, 132,	15.9	2
271	Pancreatic Cancer: Pathogenesis, Screening, Diagnosis and Treatment.. *Gastroenterology*, **2022**,	13.3	10
270	Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma. *Clinical Cancer Research*, **2021**, 27, 1278-1286	12.9	11
269	Implantation of a neoantigen-targeted hydrogel vaccine prevents recurrence of pancreatic adenocarcinoma after incomplete resection. *OncoImmunology*, **2021**, 10, 2001159	7.2	1
268	IgE-Based Therapeutic Combination Enhances Antitumor Response in Preclinical Models of Pancreatic Cancer. *Molecular Cancer Therapeutics*, **2021**, 20, 2457-2468	6.1	
267	Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome. *Cancer Discovery*, **2021**, 11, 2014-2031	24.4	16
266	A global live cell barcoding approach for multiplexed mass cytometry profiling of mouse tumors. *JCI Insight*, **2021**, 6,	9.9	3
265	Analysis of immune checkpoint blockade biomarkers in elderly patients using large-scale cancer genomics data.. *Journal of Clinical Oncology*, **2021**, 39, 2543-2543	2.2	
264	Multi-omic profiling of lung and liver tumor microenvironments of metastatic pancreatic cancer reveals site-specific immune regulatory pathways. *Genome Biology*, **2021**, 22, 154	18.3	6
263	Phase I Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844). *Clinical Cancer Research*, **2021**, 27, 5828-5837	12.9	5
262	Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade. *Science*, **2021**, 372,	33.3	25
261	Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer. *Clinical Cancer Research*, **2021**, 27, 4574-4586	12.9	11
260	Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited. *Cancer Discovery*, **2021**, 11, 233-236	24.4	95

259	Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017. *Cancer Letters*, **2021**, 497, 221-228	9.9	7
258	An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor Growth. *Cancer Discovery*, **2021**, 11, 696-713	24.4	9
257	A feasibility study of combined epigenetic and vaccine therapy in advanced colorectal cancer with pharmacodynamic endpoint. *Clinical Epigenetics*, **2021**, 13, 25	7.7	3
256	How Did We Get a COVID-19 Vaccine in Less Than 1 Year?. *Clinical Cancer Research*, **2021**, 27, 2136-2138	12.9	5
255	Cancer Moonshot 2.0. *Lancet Oncology, The*, **2021**, 22, 164-165	21.7	3
254	Neoadjuvant Cabozantinib and Nivolumab Converts Locally Advanced HCC into Resectable Disease with Enhanced Antitumor Immunity. *Nature Cancer*, **2021**, 2, 891-903	15.4	18
253	Context-Dependent Immunomodulatory Effects of MEK Inhibition Are Enhanced with T-cell Agonist Therapy. *Cancer Immunology Research*, **2021**, 9, 1187-1201	12.5	6
252	From bench to bedside: Single-cell analysis for cancer immunotherapy. *Cancer Cell*, **2021**, 39, 1062-1080	24.3	14
251	Evaluating the impact of age on immune checkpoint therapy biomarkers. *Cell Reports*, **2021**, 36, 109599	10.6	3
250	Transfer learning between preclinical models and human tumors identifies a conserved NK cell activation signature in anti-CTLA-4 responsive tumors. *Genome Medicine*, **2021**, 13, 129	14.4	2
249	Analysis of Population Differences in Digital Conversations About Cancer Clinical Trials: Advanced Data Mining and Extraction Study. *JMIR Cancer*, **2021**, 7, e25621	3.2	0
248	Forecasting cancer: from precision to predictive medicine.. *Med*, **2021**, 2, 1004-1010	31.7	0
247	Pharmacodynamic measures within tumors expose differential activity of PD(L)-1 antibody therapeutics. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	2
246	Systemic inhibition of PTPN22 augments anticancer immunity. *Journal of Clinical Investigation*, **2021** ,	15.9	5
245	Translational Advances in Cancer Prevention Agent Development (TACPAD) Virtual Workshop on Immunomodulatory Agents: Report.. *Journal of Cancer Prevention*, **2021**, 26, 309-317	3	
244	Macrophage-Targeting by CSF1/1R Blockade in Pancreatic Cancers.. *Cancer Research*, **2021**, 81, 6071-6073	10.1	1
243	Regulation of the tumor immune microenvironment and vascular normalization in TNBC murine models by a novel peptide. *OncoImmunology*, **2020**, 9, 1760685	7.2	5
242	The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities. *Nature Reviews Clinical Oncology*, **2020**, 17, 527-540	19.4	221

241	Inhibition of miR-21 Regulates Mutant KRAS Effector Pathways and Intercepts Pancreatic Ductal Adenocarcinoma Development. *Cancer Prevention Research*, **2020**, 13, 569-582	3.2	5
240	Single-Cell Immune Competency Signatures Associate with Survival in Phase II GVAX and CRS-207 Randomized Studies in Patients with Metastatic Pancreatic Cancer. *Cancer Immunology Research*, **2020**, 8, 609-617	12.5	4
239	Nanoparticle interactions with immune cells dominate tumor retention and induce T cell-mediated tumor suppression in models of breast cancer. *Science Advances*, **2020**, 6, eaay1601	14.3	63
238	Conducting a Virtual Clinical Trial in HER2-Negative Breast Cancer Using a Quantitative Systems Pharmacology Model With an Epigenetic Modulator and Immune Checkpoint Inhibitors. *Frontiers in Bioengineering and Biotechnology*, **2020**, 8, 141	5.8	17
237	A Phase II Study of Allogeneic GM-CSF-Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer. *Clinical Cancer Research*, **2020**, 26, 5129-5139	12.9	28
236	Tumor Mutational Burden, Toxicity, and Response of Immune Checkpoint Inhibitors Targeting PD(L)1, CTLA-4, and Combination: A Meta-regression Analysis. *Clinical Cancer Research*, **2020**, 26, 4842-4851	12.9	33
235	Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future. *Lancet Oncology, The*, **2020**, 21, e135-e145	21.7	78
234	Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer. *Clinical Cancer Research*, **2020**, 26, 3578-3588	12.9	36
233	Multipanel mass cytometry reveals anti-PD-1 therapy-mediated B and T cell compartment remodeling in tumor-draining lymph nodes. *JCI Insight*, **2020**, 5,	9.9	8
232	Effects of B cell-activating factor on tumor immunity. *JCI Insight*, **2020**, 5,	9.9	12
231	Role of in silico structural modeling in predicting immunogenic neoepitopes for cancer vaccine development. *JCI Insight*, **2020**, 5,	9.9	6
230	Disrupting a converging metabolic target turns up the immunologic-heat in pancreatic tumors. *Journal of Clinical Investigation*, **2020**, 130, 71-73	15.9	4
229	An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in patients with metastatic pancreatic adenocarcinoma. *Oncotarget*, **2020**, 11, 1929-1941	3.3	3
228	Cancer cells educate natural killer cells to a metastasis-promoting cell state. *Journal of Cell Biology*, **2020**, 219,	7.3	34
227	Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade. *Clinical Cancer Research*, **2020**, 26, 545-551	12.9	43
226	A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer. *Cancer Medicine*, **2020**, 9, 1485-1494	4.8	25
225	Carcinoma of the Pancreas **2020**, 1342-1360.e7		0
224	Integrated immunological analysis of a successful conversion of locally advanced hepatocellular carcinoma to resectability with neoadjuvant therapy **2020**, 8,		6

223	Digital Pathology Analysis Quantifies Spatial Heterogeneity of CD3, CD4, CD8, CD20, and FoxP3 Immune Markers in Triple-Negative Breast Cancer. *Frontiers in Physiology*, **2020**, 11, 583333	4.6	12
222	Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic Cancer. *Annals of Surgery*, **2020**, 272, 427-435	7.8	18
221	NF-Β p50-deficient immature myeloid cell (p50-IMC) adoptive transfer slows the growth of murine prostate and pancreatic ductal carcinoma **2020**, 8,		6
220	Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma **2020**, 8,		17
219	Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma. *Cancer Research*, **2019**, 79, 4326-4330	10.1	57
218	Immunopathologic Stratification of Colorectal Cancer for Checkpoint Blockade Immunotherapy. *Cancer Immunology Research*, **2019**, 7, 1574-1579	12.5	21
217	Targeting Mechanoresponsive Proteins in Pancreatic Cancer: 4-Hydroxyacetophenone Blocks Dissemination and Invasion by Activating MYH14. *Cancer Research*, **2019**, 79, 4665-4678	10.1	24
216	Human Cancer Cell Membrane-Coated Biomimetic Nanoparticles Reduce Fibroblast-Mediated Invasion and Metastasis and Induce T-Cells. *ACS Applied Materials & Interfaces*, **2019**, 11, 7850-7861	9.5	59
215	Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study). *Clinical Cancer Research*, **2019**, 25, 5493-5502	12.9	99
214	Dissecting the Stromal Signaling and Regulation of Myeloid Cells and Memory Effector T Cells in Pancreatic Cancer. *Clinical Cancer Research*, **2019**, 25, 5351-5363	12.9	36
213	Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts. *Cancer Discovery*, **2019**, 9, 1102-1123	24.4	479
212	Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies **2019**, 7, 132		27
211	Current Status of Immunotherapies for Treating Pancreatic Cancer. *Current Oncology Reports*, **2019**, 21, 60	6.3	24
210	Programmed Cell Death Ligand-1 (PD-L1) and CD8 Expression Profiling Identify an Immunologic Subtype of Pancreatic Ductal Adenocarcinomas with Favorable Survival. *Cancer Immunology Research*, **2019**, 7, 886-895	12.5	76
209	Multiple Immune-Suppressive Mechanisms in Fibrolamellar Carcinoma. *Cancer Immunology Research* , **2019**, 7, 805-812	12.5	9
208	Anti-CTLA-4 synergizes with dendritic cell-targeted vaccine to promote IL-3-dependent CD4 effector T cell infiltration into murine pancreatic tumors. *Annals of the New York Academy of Sciences*, **2019**, 1445, 62-73	6.5	9
207	Differential Variation Analysis Enables Detection of Tumor Heterogeneity Using Single-Cell RNA-Sequencing Data. *Cancer Research*, **2019**, 79, 5102-5112	10.1	10
206	Axon Guidance Molecules Promote Perineural Invasion and Metastasis of Orthotopic Pancreatic Tumors in Mice. *Gastroenterology*, **2019**, 157, 838-850.e6	13.3	37

205	Clinical Response of Live-Attenuated, Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma. *Clinical Cancer Research*, **2019**, 25, 5787-5798	12.9	33
204	MEK inhibition suppresses B regulatory cells and augments anti-tumor immunity. *PLoS ONE*, **2019**, 14, e0224600	3.7	12
203	PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. *JCI Insight*, **2019**, 4,	9.9	172
202	Peptide-based PET quantifies target engagement of PD-L1 therapeutics. *Journal of Clinical Investigation*, **2019**, 129, 616-630	15.9	56
201	Immunotherapy transforms cancer treatment. *Journal of Clinical Investigation*, **2019**, 129, 46-47	15.9	21
200	Equity and diversity in academic medicine: a perspective from the JCI editors. *Journal of Clinical Investigation*, **2019**, 129, 3974-3977	15.9	2
199	Tumor mutational burden (TMB) and response rates to immune checkpoint inhibitors (ICIs) targeting PD-1, CTLA-4, and combination.. *Journal of Clinical Oncology*, **2019**, 37, 2578-2578	2.2	3
198	A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell-Mediated Anticancer Activity. *Cancer Immunology Research*, **2019**, 7, 428-442	12.5	59
197	Prophylactic Vaccines for Nonviral Cancers. *Annual Review of Cancer Biology*, **2018**, 2, 195-211	13.3	3
196	Immunotherapy for Pancreatic Cancer **2018**, 856-864		
195	Pancreatic cancer: Next-generation algorithms for neoantigen selection. *Nature Reviews Gastroenterology and Hepatology*, **2018**, 15, 135-136	24.2	1
194	Vaccine Therapy and Immunotherapy for Pancreatic Cancer **2018**, 1461-1505		
193	Multiplex Proximity Ligation Assay to Identify Potential Prognostic Biomarkers for Improved Survival in Locally Advanced Pancreatic Cancer Patients Treated With Stereotactic Body Radiation Therapy. *International Journal of Radiation Oncology Biology Physics*, **2018**, 100, 486-489	4	0
192	Immune Modulation Therapy and Imaging: Workshop Report. *Journal of Nuclear Medicine*, **2018**, 59, 410-417	8.9	19
191	Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer. *JCI Insight*, **2018**, 3,	9.9	73
190	Emerging strategies for combination checkpoint modulators in cancer immunotherapy. *Journal of Clinical Investigation*, **2018**, 128, 3209-3218	15.9	107
189	Stereotactic Body Radiation Therapy for Isolated Local Recurrence After Surgical Resection of Pancreatic Ductal Adenocarcinoma Appears to be Safe and Effective. *Annals of Surgical Oncology*, **2018**, 25, 280-289	3.1	20
188	T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma. *JCI Insight*, **2018**, 3,	9.9	128

187	Transcriptional profiling identifies novel regulators of macrophage polarization. *PLoS ONE*, **2018**, 13, e0208602	3.7	47
186	Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer **2018**, 6, 118		30
185	Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs. *Cancer Immunology Research*, **2018**, 6, 1561-1577	12.5	85
184	Hedgehog signaling stimulates Tenascin C to promote invasion of pancreatic ductal adenocarcinoma cells through Annexin A2. *Cell Adhesion and Migration*, **2017**, 11, 514-523	3.2	7
183	Targeting neoantigens to augment antitumour immunity. *Nature Reviews Cancer*, **2017**, 17, 209-222	31.3	449
182	A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice. *Cancer Immunology Research*, **2017**, 5, 468-479	12.5	87
181	Proteins (Mesothelin) **2017**, 441-450		
180	Quantitative Multiplex Immunohistochemistry Reveals Myeloid-Inflamed Tumor-Immune Complexity Associated with Poor Prognosis. *Cell Reports*, **2017**, 19, 203-217	10.6	278
179	Strategies for Increasing Pancreatic Tumor Immunogenicity. *Clinical Cancer Research*, **2017**, 23, 1656-1669	12.9	92
178	Future cancer research priorities in the USA: a Lancet Oncology Commission. *Lancet Oncology, The*, **2017**, 18, e653-e706	21.7	106
177	A Blueprint to Advance Colorectal Cancer Immunotherapies. *Cancer Immunology Research*, **2017**, 5, 942-949	12.5	40
176	Characterization of the Immune Microenvironment in Hepatocellular Carcinoma. *Clinical Cancer Research*, **2017**, 23, 7333-7339	12.9	76
175	Dual Inhibition of Hedgehog and c-Met Pathways for Pancreatic Cancer Treatment. *Molecular Cancer Therapeutics*, **2017**, 16, 2399-2409	6.1	19
174	Heterogeneous Stromal Signaling within the Tumor Microenvironment Controls the Metastasis of Pancreatic Cancer. *Cancer Research*, **2017**, 77, 41-52	10.1	61
173	Tumor Mutational Burden and Response Rate to PD-1 Inhibition. *New England Journal of Medicine*, **2017**, 377, 2500-2501	59.2	1353
172	Results from a phase 2b, randomized, multicenter study of GVAX pancreas and CRS-207 compared to chemotherapy in adults with previously-treated metastatic pancreatic adenocarcinoma (ECLIPSE Study).. *Journal of Clinical Oncology*, **2017**, 35, 345-345	2.2	33
171	Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer. *Oncotarget*, **2017**, 8, 44073-44081	3.3	45
170	Stromal Annexin A2 expression is predictive of decreased survival in pancreatic cancer. *Oncotarget*, **2017**, 8, 106405-106414	3.3	11

169	Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors. *Oncotarget*, **2017**, 8, 114268-114280	33	108
168	Vaccine Therapy and Immunotherapy for Pancreatic Cancer **2017**, 1-45		
167	De novo DNA methylation by DNA methyltransferase 3a controls early effector CD8+ T-cell fate decisions following activation. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 10631-6	11.5	71
166	Leveraging premalignant biology for immune-based cancer prevention. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 10750-8	11.5	44
165	Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer. *International Journal of Radiation Oncology Biology Physics*, **2016**, 94, 571-9	4	123
164	Using Quantitative Seroproteomics to Identify Antibody Biomarkers in Pancreatic Cancer. *Cancer Immunology Research*, **2016**, 4, 225-33	12.5	19
163	Current progress in immunotherapy for pancreatic cancer. *Cancer Letters*, **2016**, 381, 244-51	9.9	120
162	Genomic change in hepatitis B virus associated with development of hepatocellular carcinoma. *World Journal of Gastroenterology*, **2016**, 22, 5393-9	5.6	8
161	Vaccines and Their Role in CD8 T Cell-Mediated Antitumor Immunity **2016**, 534-541		
160	A U.S. "Cancer Moonshot" to accelerate cancer research. *Science*, **2016**, 353, 1105-6	33.3	38
159	Mesothelin Immunotherapy for Cancer: Ready for Prime Time?. *Journal of Clinical Oncology*, **2016**, 34, 4171-4179	2.2	173
158	Cancer-Associated Fibroblasts in Pancreatic Cancer Are Reprogrammed by Tumor-Induced Alterations in Genomic DNA Methylation. *Cancer Research*, **2016**, 76, 5395-404	10.1	68
157	Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells. *Cancer Immunology Research*, **2015**, 3, 412-23	12.5	220
156	Special Conference on Tumor Immunology and Immunotherapy: A New Chapter. *Cancer Immunology Research*, **2015**, 3, 590-597	12.5	13
155	Semaphorin 3D autocrine signaling mediates the metastatic role of annexin A2 in pancreatic cancer. *Science Signaling*, **2015**, 8, ra77	8.8	61
154	Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. *Journal of Clinical Oncology*, **2015**, 33, 1325-33	2.2	398
153	Nonviral oncogenic antigens and the inflammatory signals driving early cancer development as targets for cancer immunoprevention. *Clinical Cancer Research*, **2015**, 21, 1549-57	12.9	33
152	Immune Therapy in GI Malignancies: A Review. *Journal of Clinical Oncology*, **2015**, 33, 1745-53	2.2	29

151	PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors. *Journal of Immunotherapy*, **2015**, 38, 1-11	5	270
150	The prognostic value of stroma in pancreatic cancer in patients receiving adjuvant therapy. *Hpb*, **2015**, 17, 292-8	3.8	50
149	Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival. *International Journal of Cancer*, **2015**, 136, 127-37	7.5	31
148	Randomized phase II study of the safety, efficacy, and immune response of GVAX pancreas vaccine (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR).. *Journal of Clinical Oncology*, **2015**, 33, TPS4148-TPS4148	2.2	5
147	TGF- blockade depletes T regulatory cells from metastatic pancreatic tumors in a vaccine dependent manner. *Oncotarget*, **2015**, 6, 43005-15	3.3	48
146	Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. *Cancer Immunology Research*, **2014**, 2, 616-31	12.5	322
145	Specificity delivers: therapeutic role of tumor antigen-specific antibodies in pancreatic cancer. *Seminars in Oncology*, **2014**, 41, 559-75	5.5	3
144	Immunobiology of radiotherapy: new paradigms. *Radiation Research*, **2014**, 182, 123-5	3.1	27
143	A safety and feasibility study of an allogeneic colon cancer cell vaccine administered with a granulocyte-macrophage colony stimulating factor-producing bystander cell line in patients with metastatic colorectal cancer. *Annals of Surgical Oncology*, **2014**, 21, 3931-7	3.1	25
142	Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia. *Cancer Cell*, **2014**, 25, 621-37	24.3	235
141	A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice. *Gastroenterology*, **2014**, 146, 1784-94.e6	13.3	95
140	A preclinical murine model of hepatic metastases. *Journal of Visualized Experiments*, **2014**, 51677	1.6	70
139	PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibition. *Journal of Pathology*, **2014**, 234, 502-13	9.4	34
138	Can we predict mutant neoepitopes in human cancers for patient-specific vaccine therapy?. *Cancer Immunology Research*, **2014**, 2, 518-21	12.5	3
137	A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer. *Cancer Immunology Research*, **2014**, 2, 949-61	12.5	51
136	Fusion protein of mutant B7-DC and Fc enhances the antitumor immune effect of GM-CSF-secreting whole-cell vaccine. *Journal of Immunotherapy*, **2014**, 37, 147-54	5	2
135	Priming the pancreatic cancer tumor microenvironment for checkpoint-inhibitor immunotherapy. *OncoImmunology*, **2014**, 3, e962401	7.2	31
134	Cancer immunoprevention--the next frontier. *Cancer Prevention Research*, **2014**, 7, 1072-80	3.2	20

133	Apoptosis-regulated low-avidity cancer-specific CD8(+) T cells can be rescued to eliminate HER2/neu-expressing tumors by costimulatory agonists in tolerized mice. *Cancer Immunology Research*, **2014**, 2, 307-19	12.5	16
132	Carcinoma of the Pancreas **2014**, 1397-1415.e7		1
131	Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma. *Gastroenterology*, **2013**, 144, 1230-40	13.3	198
130	Mapping patterns of local recurrence after pancreaticoduodenectomy for pancreatic adenocarcinoma: a new approach to adjuvant radiation field design. *International Journal of Radiation Oncology Biology Physics*, **2013**, 87, 1007-15	4	46
129	Immunotherapy and Cancer Therapeutics **2013**, 415-432		1
128	Effects of genomic changes in hepatitis B virus on postoperative recurrence and survival in patients with hepatocellular carcinoma. *Annals of Surgical Oncology*, **2013**, 20, 1216-22	3.1	10
127	Development of a cytokine-modified allogeneic whole cell pancreatic cancer vaccine. *Methods in Molecular Biology*, **2013**, 980, 175-203	1.4	9
126	Immunotherapy in preneoplastic disease: targeting early procarcinogenic inflammatory changes that lead to immune suppression and tumor tolerance. *Annals of the New York Academy of Sciences*, **2013**, 1284, 12-6	6.5	7
125	Low total lymphocyte count is associated with poor survival in patients with resected pancreatic adenocarcinoma receiving a GM-CSF secreting pancreatic tumor vaccine. *Annals of Surgical Oncology*, **2013**, 20 Suppl 3, S725-30	3.1	27
124	Proteins (Mesothelin) **2013**, 1-10		
123	Personalized chemotherapy profiling using cancer cell lines from selectable mice. *Clinical Cancer Research*, **2013**, 19, 1139-46	12.9	21
122	Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. *Journal of Immunotherapy*, **2013**, 36, 382-9	5	393
121	Harnessing immune responses in the tumor microenvironment: all signals needed. *Clinical Cancer Research*, **2013**, 19, 6061-3	12.9	12
120	Vaccine therapy for pancreatic cancer. *OncoImmunology*, **2013**, 2, e26662	7.2	40
119	Next-generation cancer vaccine approaches: integrating lessons learned from current successes with promising biotechnologic advances. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2013**, 11, 766-72	7.3	9
118	Immunohistochemical staining of B7-H1 (PD-L1) on paraffin-embedded slides of pancreatic adenocarcinoma tissue. *Journal of Visualized Experiments*, **2013**,	1.6	23
117	Peptidases released by necrotic cells control CD8+ T cell cross-priming. *Journal of Clinical Investigation*, **2013**, 123, 4755-68	15.9	17
116	Women in Oncology: Progress, Challenges, and Keys to Success. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2013**, 33, 448-455	7.1	2

115	Interim safety and efficacy analysis of a phase II, randomized study of GVAX pancreas and CRS-207 immunotherapy in patients with metastatic pancreatic cancer.. *Journal of Clinical Oncology*, **2013**, 31, 4040-4040	2.2	6
114	TH17 cells and early pancreatic tumorigenesis.. *Journal of Clinical Oncology*, **2013**, 31, 144-144	2.2	
113	Whole cell vaccines--past progress and future strategies. *Seminars in Oncology*, **2012**, 39, 276-86	5.5	89
112	Evaluation of predictive variables in locally advanced pancreatic adenocarcinoma patients receiving definitive chemoradiation. *Practical Radiation Oncology*, **2012**, 2, 77-85	2.8	23
111	Rapid characterization of candidate biomarkers for pancreatic cancer using cell microarrays (CMAs). *Journal of Proteome Research*, **2012**, 11, 5556-63	5.6	13
110	Development of a novel preclinical pancreatic cancer research model: bioluminescence image-guided focal irradiation and tumor monitoring of orthotopic xenografts. *Translational Oncology*, **2012**, 5, 77-84	4.9	46
109	The determinants of tumour immunogenicity. *Nature Reviews Cancer*, **2012**, 12, 307-13	31.3	248
108	Annexin A2 is a new antigenic target for pancreatic cancer immunotherapy. *OncoImmunology*, **2012**, 1, 112-114	7.2	23
107	Targeting the right regulatory T-cell population for tumor immunotherapy. *OncoImmunology*, **2012**, 1, 1191-1193	7.2	13
106	Concomitant targeting of tumor cells and induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer. *Cancer Research*, **2012**, 72, 4417-28	10.1	36
105	A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. *Clinical Cancer Research*, **2012**, 18, 858-68	12.9	257
104	Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. *Cancer Research*, **2012**, 72, 3439-44	10.1	181
103	Vaccines for pancreatic cancer. *Cancer Journal (Sudbury, Mass)*, **2012**, 18, 642-52	2.2	31
102	Trafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cells. *PLoS ONE*, **2012**, 7, e31962	3.7	38
101	Patient retention and costs associated with a pancreatic multidisciplinary clinic.. *Journal of Clinical Oncology*, **2012**, 30, 96-96	2.2	
100	Tyrosine 23 phosphorylation-dependent cell-surface localization of annexin A2 is required for invasion and metastases of pancreatic cancer. *PLoS ONE*, **2011**, 6, e19390	3.7	130
99	A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation. *Annals of Surgery*, **2011**, 253, 328-35	7.8	301
98	Increased expression of DNA repair genes in invasive human pancreatic cancer cells. *Pancreas*, **2011** , 40, 730-9	2.6	58

97	CD8+ Foxp3+ tumor infiltrating lymphocytes accumulate in the context of an effective anti-tumor response. *International Journal of Cancer*, **2011**, 129, 636-47	7.5	20
96	Nondominant CD8 T cells are active players in the vaccine-induced antitumor immune response. *Journal of Immunology*, **2011**, 186, 3847-57	5.3	16
95	Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. *Journal of Clinical Oncology*, **2010**, 28, 4390-9	2.2	243
94	Cellular vaccine approaches. *Cancer Journal (Sudbury, Mass)*, **2010**, 16, 304-10	2.2	93
93	Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice. *Cellular Immunology*, **2010**, 263, 79-87	4.4	100
92	Vaccine Therapy and Immunotherapy for Pancreatic Cancer **2010**, 1269-1318		
91	Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. *Science*, **2009**, 324, 217	33.3	608
90	Genetic mutations associated with cigarette smoking in pancreatic cancer. *Cancer Research*, **2009**, 69, 3681-8	10.1	88
89	Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. *Journal of Clinical Oncology*, **2009**, 27, 5911-8	2.2	178
88	SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. *Clinical Cancer Research*, **2009**, 15, 4674-9	12.9	275
87	OX40 costimulation can abrogate Foxp3+ regulatory T cell-mediated suppression of antitumor immunity. *International Journal of Cancer*, **2009**, 125, 630-8	7.5	56
86	Use of tumour-responsive T cells as cancer treatment. *Lancet, The*, **2009**, 373, 673-83	40	127
85	Effective depletion of regulatory T cells allows the recruitment of mesothelin-specific CD8 T cells to the antitumor immune response against a mesothelin-expressing mouse pancreatic adenocarcinoma. *Clinical and Translational Science*, **2008**, 1, 228-39	4.9	58
84	Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. *Science*, **2008**, 321, 1801-6	33.3	3223
83	Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. *Clinical Cancer Research*, **2008**, 14, 1455-63	12.9	265
82	Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. *Journal of Clinical Oncology*, **2008**,	2.2	290
81	Vaccine impedes the development of reflux-induced esophageal cancer in a surgical rat model: efficacy of the vaccine in a post-Barrett's esophagus setting. *Digestive Diseases and Sciences*, **2008**, 53, 2858-67	4	5
80	Vaccine impedes the development of reflux-induced esophageal cancer in a surgical rat model: efficacy of the vaccine in a Pre-Barrett's esophagus setting. *Journal of Gastrointestinal Surgery*, **2008**, 12, 2-7; discussion 7-9	3.3	12

79	Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs. *Journal of Clinical Investigation*, **2008**, 118, 1700-11	15.9	70
78	Development of Vaccine Therapy for Pancreas Cancer **2008**, 683-704		
77	Immunotherapy and Cancer Therapeutics: Why Partner? **2007**, 207-233		4
76	Cytogenetic characterization and gene expression profiling in the rat reflux-induced esophageal tumor model. *Journal of Thoracic and Cardiovascular Surgery*, **2007**, 133, 763-9	1.5	28
75	Cancer immunologists and cancer biologists: why we didn₱ talk then but need to now. *Cancer Research*, **2007**, 67, 3500-4	10.1	78
74	A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. *Clinical Cancer Research*, **2007**, 13, 3951-9	12.9	169
73	Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion. *Cancer Research*, **2007**, 67, 1832-41	10.1	69
72	Alteration of cellular and humoral immunity by mutant p53 protein and processed mutant peptide in head and neck cancer. *Clinical Cancer Research*, **2007**, 13, 7199-206	12.9	23
71	Alphaviral vector-transduced dendritic cells are successful therapeutic vaccines against neu-overexpressing tumors in wild-type mice. *Vaccine*, **2007**, 25, 6604-12	4.1	31
70	Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. *Cancer Immunity*, **2007**, 7, 20		115
69	Ductal access for prevention and therapy of mammary tumors. *Cancer Research*, **2006**, 66, 638-45	10.1	64
68	OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen. *Journal of Immunology*, **2006**, 176, 974-83	5.3	94
67	Mechanisms of immune evasion by tumors. *Advances in Immunology*, **2006**, 90, 51-81	5.6	497
66	Manipulating Immunological Checkpoints to Maximize Antitumor Immunity **2006**, 331-353		
65	Genes to vaccines for immunotherapy: how the molecular biology revolution has influenced cancer immunology. *Molecular Cancer Therapeutics*, **2005**, 4, 1645-52	6.1	26
64	Development of a cytokine-modified allogeneic whole cell pancreatic cancer vaccine. *Methods in Molecular Medicine*, **2005**, 103, 299-327		5
63	Immunotherapy for pancreatic cancer - science driving clinical progress. *Nature Reviews Cancer*, **2005**, 5, 459-67	31.3	157
62	Fatty acid synthase inhibitors are chemopreventive for mammary cancer in neu-N transgenic mice. *Oncogene*, **2005**, 24, 39-46	9.2	132

61	Tumor-specific CD4+ T cells from a patient with renal cell carcinoma recognize diverse shared antigens. *International Journal of Cancer*, **2005**, 115, 752-9	7.5	21
60	Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse. *Journal of Immunology*, **2005**, 175, 3663-73	5.3	96
59	Allergies and the risk of pancreatic cancer: a meta-analysis with review of epidemiology and biological mechanisms. *Cancer Epidemiology Biomarkers and Prevention*, **2005**, 14, 1908-16	4	88
58	Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. *Cancer Research*, **2005**, 65, 8059-64	10.1	152
57	Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. *Journal of Experimental Medicine*, **2005**, 201, 1591-602	16.6	369
56	Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity. *Endocrine-Related Cancer*, **2005**, 12, 1-17	5.7	64
55	Cancer vaccines in combination with multimodality therapy. *Cancer Treatment and Research*, **2005**, 123, 227-45	3.5	12
54	Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocyte-macrophage colony-stimulating factor gene-transduced renal tumor cell vaccine. *Cancer Research*, **2005**, 65, 1079-88	10.1	28
53	A phase I vaccine safety and chemotherapy dose-finding trial of an allogeneic GM-CSF-secreting breast cancer vaccine given in a specifically timed sequence with immunomodulatory doses of cyclophosphamide and doxorubicin. *Human Gene Therapy*, **2004**, 15, 313-37	4.8	32
52	Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. *Journal of Experimental Medicine*, **2004**, 200, 297-306	16.6	278
51	Augmenting the potency of breast cancer vaccines: combined modality immunotherapy. *Breast Disease*, **2004**, 20, 13-24	1.6	18
50	Gene-Modified Tumor-Cell Vaccines **2004**, 253-273		
49	Lentivirus-mediated gene transfer and expression in established human tumor antigen-specific cytotoxic T cells and primary unstimulated T cells. *Human Gene Therapy*, **2003**, 14, 1089-105	4.8	43
48	HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic mice. *Journal of Immunology*, **2003**, 171, 2161-9	5.3	87
47	Cancer Vaccines: An Old Idea Comes of Age. *Cancer Biology and Therapy*, **2003**, 2, 160-167	4.6	1
46	Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice. *Journal of Immunology*, **2003**, 170, 4273-80	5.3	83
45	Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo. *International Journal of Cancer*, **2003**, 103, 205-11	7.5	171
44	Major histocompatibility complex class II-restricted presentation of a cytosolic antigen by autophagy. *European Journal of Immunology*, **2003**, 33, 1250-9	6.1	271

43	Genetically engineered tumor cell vaccine in a head and neck cancer model. *Laryngoscope*, **2003**, 113, 552-6	3.6	18
42	Spatial distribution of tumor vaccine improves efficacy. *Laryngoscope*, **2003**, 113, 1401-5	3.6	6
41	Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. *American Journal of Pathology*, **2003**, 162, 1151-62	5.8	397
40	Generation of Renal Cell Carcinoma-specific CD4+/CD8+T Cells Restricted by an HLA-39 from a RCC Patient Vaccinated with GM-CSF Gene-Transduced Tumor Cells. *Immune Network*, **2003**, 3, 96	6.1	
39	Cancer vaccines: an old idea comes of age. *Cancer Biology and Therapy*, **2003**, 2, S161-8	4.6	14
38	Toward a breast cancer vaccine: work in progress. *Oncology*, **2003**, 17, 1200-11; discussion 1214, 1217-8	1.8	8
37	Focus on pancreas cancer. *Cancer Cell*, **2002**, 2, 25-8	24.3	185
36	Aberrant CpG island methylation in cancer cell lines arises in the primary cancers from which they were derived. *Oncogene*, **2002**, 21, 2114-7	9.2	44
35	Pancreatic cancer. *Current Problems in Cancer*, **2002**, 26, 176-275	2.3	221
34	Cytokine modified tumor vaccines. *Surgical Oncology Clinics of North America*, **2002**, 11, 681-96	2.7	10
33	Cytokine gene-modified cell-based cancer vaccines. *Methods in Molecular Medicine*, **2002**, 69, 233-57		7
32	Cancer vaccines. *Current Protocols in Human Genetics*, **2001**, Chapter 13, Unit 13.8	3.2	
31	Improved gene transfer efficiency to primary and established human pancreatic carcinoma target cells via epidermal growth factor receptor and integrin-targeted adenoviral vectors. *Gene Therapy*, **2001**, 8, 969-76	4	90
30	An immunodominant MHC class II-restricted tumor antigen is conformation dependent and binds to the endoplasmic reticulum chaperone, calreticulin. *Journal of Immunology*, **2001**, 167, 147-55	5.3	15
29	Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. *Journal of Clinical Oncology*, **2001**, 19, 145-56	2.2	485
28	Chemotherapy: friend or foe to cancer vaccines?. *Current Opinion in Molecular Therapeutics*, **2001**, 3, 77-84		38
27	Progress Toward Cancer Vaccines. *Hospital Practice (1995)*, **2000**, 35, 49-65	2.2	2
26	Intracranial paracrine interleukin-2 therapy stimulates prolonged antitumor immunity that extends outside the central nervous system. *Journal of Immunotherapy*, **2000**, 23, 438-48	5	26

25	Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival. *International Journal of Radiation Oncology Biology Physics*, **2000**, 48, 1089-96	4	39
24	Compromised HOXA5 function can limit p53 expression in human breast tumours. *Nature*, **2000**, 405, 974-8	50.4	395
23	Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. *Immunity*, **2000**, 13, 529-38	32.3	268
22	Cancer vaccines. *Expert Opinion on Emerging Drugs*, **2000**, 5, 201-209		
21	Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. *Advances in Immunology*, **2000**, 74, 181-273	5.6	863
20	Cancer vaccines. *Journal of Clinical Oncology*, **1999**, 17, 1047-60	2.2	123
19	Immunotherapy of cancer. *Annals of the New York Academy of Sciences*, **1999**, 886, 67-72	6.5	36
18	Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine. *Human Gene Therapy*, **1998**, 9, 835-43	4.8	84
17	A phase I clinical trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinoma. *Human Gene Therapy*, **1998**, 9, 1951-71	4.8	69
16	Direct visualization of antigen-specific T cells: HTLV-1 Tax11-19- specific CD8(+) T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patients. *Proceedings of the National Academy of Sciences of the United States of America*, **1998**, 95, 7568-73	11.5	217
15	Considerations for the clinical development of cytokine gene-transduced tumor cell vaccines. *Methods*, **1997**, 12, 143-53	4.6	36
14	Pancreatic carcinoma cell killing via adenoviral mediated delivery of the herpes simplex virus thymidine kinase gene. *Annals of Surgery*, **1997**, 225, 609-18; discussion 618-20	7.8	30
13	Enhanced immune priming with spatial distribution of paracrine cytokine vaccines. *Journal of Immunotherapy*, **1996**, 19, 176-83	5	58
12	The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. *Proceedings of the National Academy of Sciences of the United States of America*, **1996**, 93, 9730-5	11.5	317
11	Murine tumor antigens: is it worth the search?. *Current Opinion in Immunology*, **1996**, 8, 622-7	7.8	38
10	Systemic and local paracrine cytokine therapies using transduced tumor cells are synergistic in treating intracranial tumors. *Journal of Immunotherapy*, **1996**, 19, 405-13	5	46
9	Phase I study of non-replicating autologous tumor cell injections using cells prepared with or without GM-CSF gene transduction in patients with metastatic renal cell carcinoma. *Human Gene Therapy*, **1995**, 6, 347-68	4.8	72
8	A reassessment of the role of B7-1 expression in tumor rejection. *Journal of Experimental Medicine*, **1995**, 182, 1415-21	16.6	162

7	Use of murine models of cytokine-secreting tumor vaccines to study feasibility and toxicity issues critical to designing clinical trials. *Journal of Immunotherapy*, **1995**, 18, 1-9	5	31
6	Simplified high-sensitivity sequencing of a major histocompatibility complex class I-associated immunoreactive peptide using matrix-assisted laser desorption/ionization mass spectrometry. *Analytical Biochemistry*, **1995**, 226, 15-25	3.1	71
5	Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. *Science*, **1994**, 264, 961-5	33.3	1022
4	Demonstration of a rational strategy for human prostate cancer gene therapy. *Journal of Urology*, **1994**, 151, 622-8	2.5	204
3	Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. *Proceedings of the National Academy of Sciences of the United States of America*, **1993**, 90, 3539-43	11.5	2355
2	Herpes simplex-1 virus thymidine kinase gene is unable to completely eliminate live, nonimmunogenic tumor cell vaccines. *Journal of Immunotherapy*, **1992**, 12, 224-30	5	59
1	Harnessing the adaptive potential of mechanoresponsive proteins to overwhelm pancreatic cancer dissemination and invasion		4